专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100158861A1 TREATING IDIOPATHIC THROMBOCYTOPENIC PURPURA WITH COMPOSITIONS COMPRISING EXTRACTS OF ASTRAGALUS MEMBRANACEUS 有权
标题翻译：用包含ASTRAGALUS MEMBRANACEUS提取物的组合物处理真菌性脑膜炎白血病
公开(公告)号：US20100158861A1
公开(公告)日：2010-06-24
申请号：US12638845
申请日：2009-12-15
申请人： Jinhua An , John M. Fidler , John H. Musser
发明人： Jinhua An , John M. Fidler , John H. Musser
IPC分类号： A61K38/20 , A61K31/7004 , A61K38/16 , A61K38/14 , A61P7/04 , A61P37/00 , A61P17/00 , A61K38/19
CPC分类号： A61K36/481 , A61K9/0019 , A61K38/1816 , A61K38/193 , A61K38/196 , A61K38/202 , A61K45/06 , A61K2236/331 , A61K2236/51 , A61K2300/00
摘要： The teachings provided herein generally relate to the preparation and uses of compositions comprising extracts of Astragalus membranaceus. The extracts are prepared from Astragalus membranaceus and can comprise, for example, an acid-modified arabinogalactan protein composition having an arabinose:galactose ratio ranging from about 3.5:1 to about 5.0:1, from about 5% to about 10% rhamnose, from about 15% to about 20% galactose, and from about 10% to about 15% glucose. The compositions can be used in the treatment of idiopathic thrombocytopenic purpura and the formulation of medicaments for such treatments.
摘要翻译：本文提供的教导通常涉及包含黄芪提取物的组合物的制备和用途。提取物由黄芪制备，并且可以包含例如具有约3.5:1至约5.0:1，约5％至约10％鼠李糖的阿拉伯糖：半乳糖比例的酸修饰的阿拉伯半乳聚糖蛋白组合物，来自约15％至约20％的半乳糖，以及约10％至约15％的葡萄糖。该组合物可用于治疗特发性血小板减少性紫癜和用于这种治疗的药物的制剂。

2. 发明授权

US08728543B2 Methods of treating idiopathic thrombocytopenic purpura with compositions comprising extracts of Astragalus membranaceus 有权
标题翻译：用包含黄芪提取物的组合物治疗特发性血小板减少性紫癜的方法
公开(公告)号：US08728543B2
公开(公告)日：2014-05-20
申请号：US13368319
申请日：2012-02-07
申请人： Jinhua An , John M. Fidler , John H. Musser
发明人： Jinhua An , John M. Fidler , John H. Musser
IPC分类号： A01N65/00
CPC分类号： A61K36/481 , A61K9/0019 , A61K38/1816 , A61K38/193 , A61K38/196 , A61K38/202 , A61K45/06 , A61K2236/331 , A61K2236/51 , A61K2300/00
摘要： The teachings provided herein generally relate to the preparation and uses of compositions comprising extracts of Astragalus membranaceus. The extracts are prepared from Astragalus membranaceus and can comprise, for example, an acid-modified arabinogalactan protein composition having an arabinose:galactose ratio ranging from about 3.5:1 to about 5.0:1, from about 5% to about 10% rhamnose, from about 15% to about 20% galactose, and from about 10% to about 15% glucose. The compositions can be used in the treatment of idiopathic thrombocytopenic purpura and the formulation of medicaments for such treatments.
摘要翻译：本文提供的教导通常涉及包含黄芪提取物的组合物的制备和用途。提取物由黄芪制备，并且可以包含例如具有约3.5:1至约5.0:1，约5％至约10％鼠李糖的阿拉伯糖：半乳糖比例的酸修饰的阿拉伯半乳聚糖蛋白组合物，来自约15％至约20％的半乳糖，以及约10％至约15％的葡萄糖。该组合物可用于治疗特发性血小板减少性紫癜和用于这种治疗的药物的制剂。

3. 发明授权

US08617906B2 Identification and screening of triptolide target molecules 失效
标题翻译：雷公藤内酯靶分子的鉴定和筛选
公开(公告)号：US08617906B2
公开(公告)日：2013-12-31
申请号：US11665177
申请日：2005-10-12
申请人： John M. Fidler , John H. Musser
发明人： John M. Fidler , John H. Musser
IPC分类号： G01N33/566 , G01N33/567 , C07D307/77 , A01N43/00
CPC分类号： G01N33/6893 , C12Q1/26 , C12Q1/32 , C12Q1/42 , C12Q1/485 , C12Q1/533 , G01N2500/00
摘要： The identification of triptolide target molecules is described. Also described are methods of screening triptolide-related compounds for binding to these molecules, including screening for enhanced and/or selective binding, and expression analysis of the target molecules in normal and in diseased tissue.
摘要翻译：描述了雷公藤内酯靶分子的鉴定。还描述了筛选与这些分子结合的雷公藤内酯相关化合物的方法，包括筛选增强和/或选择性结合，以及正常和患病组织中靶分子的表达分析。

4. 发明授权

US06569893B2 Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents 失效
标题翻译：雷公藤内酯化合物的氨基酸衍生物作为免疫调节剂和抗癌剂
公开(公告)号：US06569893B2
公开(公告)日：2003-05-27
申请号：US10098009
申请日：2002-03-14
申请人： Dongcheng Dai , John M. Fidler , John H. Musser
发明人： Dongcheng Dai , John M. Fidler , John H. Musser
IPC分类号： A61K31343
CPC分类号： C07D493/22 , A61K31/365 , Y02A50/401
摘要： Compounds which are prodrugs of triptolide or its derivatives, containing an amino acid or oligopeptide moiety, are used for anticancer or immunosuppressive treatment. The compounds are of the structure: where X1 is OH or OR1, and X2 and X3 are independently OH, OR1 or H, with the proviso that at least one of X1, X2 and X3 is OR1, and at least one of X2 and X3 is H; and R1, is selected from the group consisting of: C(═O)CHY—NHP1 (b): C(═O)CH(NHP1)—(CH2)m—C(═O)OP2 (c): C(═O)(CH2)n—CH(NHP1)—C(═O)OP2 and (d): [C(═O)CHY—NH]Z—C(═O)CHY—NHP1; (e): where Y is a side chain of a naturally occurring amino acid or a one- or two-carbon homolog thereof; P1 is selected from the group consisting of H, C(═O)OR2, and C(═O)R3, where each of R2 and R3 is independently H, alkyl, alkenyl, aryl, or aralkyl; m is an integer from 0-5; n is an integer from 0-5; z is an integer from 2-10; and P2 is selected from the group consisting of H, alkyl, alkenyl, aryl, and aralkyl.
摘要翻译：作为含有氨基酸或寡肽部分的雷公藤内酯衍生物或其衍生物的前药的化合物用于抗癌或免疫抑制治疗。该化合物具有以下结构：其中X 1是OH或OR 1，且X 2和X 3独立地是OH，OR 1或H，条件是X 1，X 2和X 3中的至少一个是OR 1，以及X 2和X 3中的至少一个是H 并且R 1选自：其中Y是天然存在的氨基酸的侧链或其一或二碳同系物; P1选自H，C（= O）OR 2和C（= O）R 3，其中R 2和R 3各自独立地为H，烷基，烯基，芳基或芳烷基; m是0-5的整数; n是0-5的整数; z是2-10的整数; 且P2选自H，烷基，烯基，芳基和芳烷基。

5. 发明申请

US20120141412A1 METHODS OF TREATING IDIOPATHIC THROMBOCYTOPENIC PURPURA WITH COMPOSITIONS COMPRISING EXTRACTS OF ASTRAGALUS MEMBRANACEUS 有权
标题翻译：用包含ASTRAGALUS膜的提取物的组合物治疗真菌性脑血管性白血病的方法
公开(公告)号：US20120141412A1
公开(公告)日：2012-06-07
申请号：US13368319
申请日：2012-02-07
申请人： JINHUA AN , John M. Fidler , John H. Musser
发明人： JINHUA AN , John M. Fidler , John H. Musser
IPC分类号： A61K36/481 , A61P7/04 , A61K31/7004 , A61K38/18 , A61K38/19 , A61K38/20
CPC分类号： A61K36/481 , A61K9/0019 , A61K38/1816 , A61K38/193 , A61K38/196 , A61K38/202 , A61K45/06 , A61K2236/331 , A61K2236/51 , A61K2300/00
摘要： The teachings provided herein generally relate to the preparation and uses of compositions comprising extracts of Astragalus membranaceus. The extracts are prepared from Astragalus membranaceus and can comprise, for example, an acid-modified arabinogalactan protein composition having an arabinose:galactose ratio ranging from about 3.5:1 to about 5.0:1, from about 5% to about 10% rhamnose, from about 15% to about 20% galactose, and from about 10% to about 15% glucose. The compositions can be used in the treatment of idiopathic thrombocytopenic purpura and the formulation of medicaments for such treatments.
摘要翻译：本文提供的教导通常涉及包含黄芪提取物的组合物的制备和用途。提取物由黄芪制备，并且可以包含例如具有约3.5:1至约5.0:1，约5％至约10％鼠李糖的阿拉伯糖：半乳糖比例的酸修饰的阿拉伯半乳聚糖蛋白组合物，来自约15％至约20％的半乳糖，以及约10％至约15％的葡萄糖。该组合物可用于治疗特发性血小板减少性紫癜和用于这种治疗的药物的制剂。

6. 发明授权

US5962516A Immunosuppressive compounds and methods 有权
标题翻译：免疫抑制化合物和方法
公开(公告)号：US5962516A
公开(公告)日：1999-10-05
申请号：US142128
申请日：1999-01-25
申请人： You Mao Qi , John H. Musser , John M. Fidler
发明人： You Mao Qi , John H. Musser , John M. Fidler
IPC分类号： A61K31/365 , A61K31/34
CPC分类号： A61K31/365
摘要： Compounds and methods for use in immunosuppressive and anti-inflammatory treatment, and for inhibiting male fertility, are described. The compounds are triptolide analogs with improved water solubility and low toxicity.
摘要翻译： PCT No.PCT / US97 / 03202 Sec。 371日期1999年1月25日 102（e）日期1999年1月25日PCT提交1997年2月28日PCT公布。第WO97 / 31921号公报日期1997年9月4日描述了用于免疫抑制和抗炎治疗和抑制雄性生育力的化合物和方法。这些化合物是具有改善的水溶性和低毒性的雷公藤内酯类似物。

7. 发明授权

US06620843B2 Anticancer treatment using triptolide prodrugs 失效
公开(公告)号：US06620843B2
公开(公告)日：2003-09-16
申请号：US09766156
申请日：2001-01-19
申请人： John M. Fidler , Ke Li
发明人： John M. Fidler , Ke Li
IPC分类号： A61K3134
CPC分类号： A61K31/336 , A61K31/343 , A61K31/365 , Y10S514/908
摘要： Water soluble triptolide prodrugs are used as anticancer agents, and are found to be more effective in vivo, at lower doses, in reducing tumor size than the widely used chemotherapeutic agents 5-fluorouracil and irinotecan.

8. 发明授权

US08137710B2 Treating idiopathic thrombocytopenic purpura with comprising extracts of Astragalus membranaceus 有权
标题翻译：治疗特发性血小板减少性紫癜，包括黄芪提取物
公开(公告)号：US08137710B2
公开(公告)日：2012-03-20
申请号：US12638845
申请日：2009-12-15
申请人： Jinhua An , John M. Fidler , John H. Musser
发明人： Jinhua An , John M. Fidler , John H. Musser
IPC分类号： A01N65/00
CPC分类号： A61K36/481 , A61K9/0019 , A61K38/1816 , A61K38/193 , A61K38/196 , A61K38/202 , A61K45/06 , A61K2236/331 , A61K2236/51 , A61K2300/00
摘要： The teachings provided herein generally relate to the preparation and uses of compositions comprising extracts of Astragalus membranaceus. The extracts are prepared from Astragalus membranaceus and can comprise, for example, an acid-modified arabinogalactan protein composition having an arabinose:galactose ratio ranging from about 3.5:1 to about 5.0:1, from about 5% to about 10% rhamnose, from about 15% to about 20% galactose, and from about 10% to about 15% glucose. The compositions can be used in the treatment of idiopathic thrombocytopenic purpura and the formulation of medicaments for such treatments.
摘要翻译：本文提供的教导通常涉及包含黄芪提取物的组合物的制备和用途。提取物由黄芪制备，并且可以包含例如具有约3.5:1至约5.0:1，约5％至约10％鼠李糖的阿拉伯糖：半乳糖比例的酸修饰的阿拉伯半乳聚糖蛋白组合物，来自约15％至约20％的半乳糖，以及约10％至约15％的葡萄糖。该组合物可用于治疗特发性血小板减少性紫癜和用于这种治疗的药物的制剂。

9. 发明申请

US20080193948A1 Identification and Screening Of Triptolide Target Molecules 失效
标题翻译：雷公藤内酯靶分子的鉴定和筛选
公开(公告)号：US20080193948A1
公开(公告)日：2008-08-14
申请号：US11665177
申请日：2005-10-12
申请人： John M. Fidler , John H. Musser
发明人： John M. Fidler , John H. Musser
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , C12Q1/26 , C12Q1/32 , C12Q1/42 , C12Q1/485 , C12Q1/533 , G01N2500/00
摘要： The identification of triptolide target molecules is described. Also described are methods of screening triptolide-related compounds for binding to these molecules, including screening for enhanced and/or selective binding, and expression analysis of the target molecules in normal and in diseased tissue.
摘要翻译：描述了雷公藤内酯靶分子的鉴定。还描述了筛选与这些分子结合的雷公藤内酯相关化合物的方法，包括筛选增强和/或选择性结合，以及正常和患病组织中靶分子的表达分析。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式